LightNews LightNews
katharinawang.bsky.social
@katharinawang.bsky.social
24 followers 16 following 0 posts
Posts Replies Media Videos
Reposted
endocrineoncology.bsky.social
New research by K Wang et al. suggest that paltusotine, a novel somatostatin analogue, could be continued during peptide receptor radionuclide therapy (PRRT) in patients with metastatic gastro-enteropancreatic neuroendocrine tumours (GEP-NETs).

🔗 Explore the findings: doi.org/10.1530/EO-25-0041
Paltusotine versus octreotide: different effects on radioligand uptake in neuroendocrine tumours in Endocrine Oncology Authors: Katharina Wang et al. Open Access. Figure 1. (A) 18F-SiTATE uptake assay using BON-1 SSTR2 cells after treatment with either paltusotine or octreotide. Cellular uptake was measured after (B) 30 min, (C) 120 min and (D) 240 min. DOTATATE acetate was used as the blocked control. The data are depicted as mean ± SD of four duplicate experiments. Molar concentrations: 100× (7.3–25.4 nM), 1,000× (73–254 nM), 2,000× (146–508 nM). Significantly lower radioligand uptake compared to the unblocked control *P < 0.05, **P < 0.01, ***P < 0.001. Endocrine Oncology 5, 1; 10.1530/EO-25-0041 Published by Bioscientifica. Society of Endocrinology.
November 4, 2025 at 11:17 AM